MRK · News · 20260825N

Melanoma Vaccine Collaboration

Merck & Co., Inc. · 2026-08-25 · Importance 31 · Surprise 42

Merck and Moderna reported positive topline Phase 3 INTerpath-001 results for intismeran autogene, an individualized neoantigen mRNA therapy combined with Keytruda in patients with resected melanoma. The combination produced significant improvements in melanoma outcomes, including recurrence-free survival, strengthening the potential for a personalized oncology platform built around Keytruda. Commercial adoption may be constrained by shared economics with Moderna and the complex, patient-specific manufacturing requirements, while the therapy is being evaluated as a way to extend Keytruda’s relevance as it approaches patent expiry.

Key facts

• On August 19, 2026, Merck and Moderna announced positive topline Phase 3 results from INTerpath-001 for intismeran autogene, an individualized neoantigen therapy paired with Keytruda in resected melanoma. source
• Merck's individualized mRNA cancer therapy intismeran, developed with Moderna, showed significant improvements in a Phase 3 melanoma trial when combined with Keytruda. source
• Merck & Co.'s stock surged by 12.6% following the Phase 3 melanoma trial results for intismeran combined with Keytruda. source
• Merck & Co.'s intismeran-plus-Keytruda combination showed improved recurrence-free survival in melanoma patients, according to reporting on the clinical data. source